IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CATTANEO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.797
AS - Asia 8.853
NA - Nord America 7.394
SA - Sud America 986
AF - Africa 219
OC - Oceania 105
Continente sconosciuto - Info sul continente non disponibili 21
Totale 29.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.026
DE - Germania 6.000
CN - Cina 2.704
SG - Singapore 2.360
IT - Italia 1.947
GB - Regno Unito 918
HK - Hong Kong 785
BR - Brasile 765
RU - Federazione Russa 691
VN - Vietnam 567
BD - Bangladesh 470
IN - India 456
FR - Francia 446
JP - Giappone 417
SE - Svezia 334
ID - Indonesia 291
NL - Olanda 267
IE - Irlanda 244
FI - Finlandia 229
CA - Canada 216
KR - Corea 154
ES - Italia 124
TR - Turchia 109
MX - Messico 91
AU - Australia 84
AT - Austria 79
TW - Taiwan 76
AR - Argentina 72
CH - Svizzera 62
PL - Polonia 58
PK - Pakistan 54
DK - Danimarca 51
TH - Thailandia 51
CI - Costa d'Avorio 48
PH - Filippine 46
BE - Belgio 43
IQ - Iraq 42
IR - Iran 41
CO - Colombia 40
UA - Ucraina 37
RO - Romania 36
SA - Arabia Saudita 34
EG - Egitto 33
IL - Israele 33
ZA - Sudafrica 33
EC - Ecuador 32
CL - Cile 30
GR - Grecia 29
JO - Giordania 26
PT - Portogallo 24
NO - Norvegia 22
TN - Tunisia 22
NZ - Nuova Zelanda 21
UZ - Uzbekistan 21
HR - Croazia 20
MY - Malesia 20
MA - Marocco 19
VE - Venezuela 19
CZ - Repubblica Ceca 18
HU - Ungheria 18
AL - Albania 15
RS - Serbia 15
EU - Europa 13
KE - Kenya 13
AE - Emirati Arabi Uniti 11
DZ - Algeria 11
LB - Libano 11
PY - Paraguay 11
BY - Bielorussia 10
LU - Lussemburgo 10
MD - Moldavia 10
ET - Etiopia 9
GT - Guatemala 9
KZ - Kazakistan 9
NP - Nepal 9
QA - Qatar 9
SK - Slovacchia (Repubblica Slovacca) 9
BA - Bosnia-Erzegovina 8
CR - Costa Rica 8
DO - Repubblica Dominicana 8
JM - Giamaica 8
PE - Perù 8
SC - Seychelles 7
UY - Uruguay 7
CY - Cipro 6
LK - Sri Lanka 6
AM - Armenia 5
HN - Honduras 5
LT - Lituania 5
NG - Nigeria 5
NI - Nicaragua 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BN - Brunei Darussalam 4
MZ - Mozambico 4
OM - Oman 4
EE - Estonia 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
Totale 29.312
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 5.010
Singapore 1.311
Ashburn 802
Hong Kong 678
Hanover 660
Southend 594
San Jose 543
Milan 503
Chandler 450
Dallas 399
Beijing 385
Council Bluffs 367
New York 260
Dublin 239
Los Angeles 238
Fairfield 228
Jakarta 215
Princeton 212
Hefei 185
Ho Chi Minh City 185
Tokyo 175
Santa Clara 160
Lauterbourg 159
Bengaluru 158
Hanoi 148
Helsinki 148
Buffalo 147
Rome 138
Moscow 123
Wilmington 120
Guangzhou 118
Seattle 103
Houston 92
Shanghai 91
Toronto 91
Cambridge 90
Woodbridge 85
São Paulo 83
Tianjin 82
Boardman 75
Cangzhou 72
Des Moines 70
Ann Arbor 69
Chicago 64
Phoenix 64
The Dalles 63
Florence 60
London 60
Amsterdam 56
Istanbul 55
Columbus 54
Hyderabad 52
Nuremberg 51
Redwood City 51
Shenzhen 50
Munich 49
Nanjing 48
San Diego 48
Abidjan 47
Montreal 47
Boston 46
Bologna 43
Hangzhou 42
Seoul 42
Dearborn 40
Taipei 39
Chennai 38
Da Nang 38
Lappeenranta 37
Atlanta 36
Bangkok 36
Mumbai 36
Paris 36
Vienna 36
Turin 35
Washington 34
Berlin 33
Brussels 31
Madrid 31
Jinan 30
Zhengzhou 29
Fuzhou 27
Naples 27
Turku 27
Amman 26
Changsha 26
Haiphong 25
Warsaw 25
San Francisco 24
Stockholm 23
Sydney 23
Rio de Janeiro 22
Silver Spring 22
Osaka 21
Pavia 21
Wuhan 21
Shenyang 20
Genoa 19
Manchester 19
Zurich 19
Totale 18.185
Salva come PNG Salva come JPEG
Nome #
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 726
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial 686
Second cancers in MPN : Survival analysis from an international study 684
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs 531
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 388
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis 362
Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients. 352
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 336
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice : Identification of risk factors and the role of prophylaxis 334
Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study 332
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia 331
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib : The multicentre retrospective RUX-IOL study 331
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 296
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis : a practical approach 284
Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with Increased blasts (<10%) or with other types of disease progression 280
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series 275
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 273
Anagrelide and Mutational Status in Essential Thrombocythemia 265
PDGFB hypomethylation is a favourable prognostic biomarker in primary myelofibrosis 242
An unusual type of myeloid sarcoma localization following myelofibrosis : a case report and literature review 242
How UGT1A1 genotype impacts on TKI efficacy and safety in chronic myeloid leukemia patients 242
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 239
Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study 235
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 234
Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers 229
CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis 224
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 220
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 219
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 218
Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma 217
Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre 214
Diabetes mellitus and TKIS treatment in chronic myeloid leukemia 214
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis 213
Impact on thrombotic risk of canonical and atypical CALR mutations in essential thrombocythemia. A single-center cohort study 213
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis 211
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study 209
Pro-atherothrombotic effect induced by tyrosine-kinase inhibitors for first-line treatment of CML patients: results of a prospective multicenter study (Kiaro trial) 205
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 203
Successful treatment with Imatinib for systemic mastocytosis associated with MDS/MPN 201
Three hematologic malignancies in the same patient : chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia 200
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 199
Neutrophilic and eosinophilic dermatoses associated with hematological malignancy 197
Breakthrough infections in MPN-COVID vaccinated patients 196
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort 196
Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera : a Case Report 195
Myelofibrosis and following chronic myeloid leukemia: imatinib and ruxolitinib treatment in two cases 194
Infectious and thrombotic complications and their prognostic impact in patients with concomitant myeloid and lymphoid neoplasms : a single-center cohort study 192
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases 191
Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review 191
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 189
Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients 186
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia : Effects on response rate, toxicity and outcome 186
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 185
The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective 185
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality 183
Cytogenetic abnormalities in primary Myelofibrosis: Clinical association and outcome in an Italian multicenter series 177
The HOCT1/ABCB1 polymorphisms don’t condition the cytogenetic and molecular response or tolerability to first-line nilotinib in chronic myeloid leukemia patients 177
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis 177
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 174
Myeloproliferative neoplasms and splanchnic vein thrombosis: Clinical and molecular features. A single-center cohort study 174
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients 173
Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event 172
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study 171
Thrombotic events in myelofibrosis: relationship with clinical and morphological characteristics, JAK2V617F mutational status and autoimmune phenomena 169
Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease 169
Imatinib and ruxolitinib association : first experience in two patients 168
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients : a real clinical problem? 167
Immune dysregulation and infectious complications in MPN patients treated with JAK inhibitors 165
Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients : A Safe and Effective Option 162
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19 159
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia 158
Osteolytic lesions in primary myelofibrosis and effect of ruxolitinib therapy : Report of a case and literature review 158
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 157
Thrombosis free survival in 734 patients with essential thrombocythemia (WHO 2016)stratified according to the revised IPSET-thrombosis score : a report of the registro italiano Trombocitemie (RIT) 157
Metabolic syndrome and TKIS treatment in chronic myeloid leukemia 151
Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment 149
Molecular analyses in the diagnosis of myeloproliferative neoplasm-related splanchnic vein thrombosis 149
Prospective evaluation of peripheral blood CD26+leukemia stem cells in chronic Myeloid Leukemia patients during TKI discontinuation (Flower-TFR Study) 148
Oxidative status in essential thrombocythemia 148
Value and limitations of targeted next-generation sequencing in idiopathic hypereosinophilia: an integrative diagnostic tool in challenging cases 147
A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation 147
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera 146
Heterogeneity among different myeloproliferative neoplasms associated with splanchnic vein thrombosis 146
Reply to: Can circulating CD34+ cells count be used for the prognosis of myelofibrosis? Probably yes, at least in patients treated with ruxolitinib 144
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIS: A feasible option also in the real-life setting? 144
Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib 142
New perspectives on polycythemia vera : from diagnosis to therapy 141
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study 141
MYSEC-Prognostic Model and previous thrombotic events predict the risk of thrombosis in post polycythemia vera and post essential thrombocythemia myelofibrosis: a study of the MYSEC Group 141
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 140
Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies 138
Lipid peroxidation and inflammatory status during TKI treatment in chronic myeloid leukemia patients: interim analysis of a prospective multicenter study 138
Could liver involvement be early detected in sickle cell disease? 138
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 137
SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 137
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy : Report of a Case 136
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 136
Chronic myeloid leukemia with extreme thrombocytocis at the diagnosis: a new subset 136
Blast transformation in myeloproliferative neoplasms : Risk factors, biological findings, and targeted therapeutic options 135
Association of platelet thromboxane inhibition by low-dose aspirin with platelet count and cytoreductive therapy in essential thrombocythemia 135
Totale 21.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.396
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202164 0 0 0 0 0 0 0 0 0 0 0 64
2021/20222.892 141 398 489 226 167 101 189 151 293 225 146 366
2022/20232.360 236 177 195 197 222 354 102 205 236 62 258 116
2023/20245.384 146 123 135 154 388 196 774 685 335 694 850 904
2024/20257.130 741 990 726 812 333 343 333 508 344 505 504 991
2025/202610.472 967 835 1.109 900 893 666 1.151 535 1.187 761 1.170 298
Totale 30.313